Biomerica's inFoods IBS Test Featured In Prestigious Journal Gastroenterology As Landmark Peer-Reviewed Study Demonstrates Symptom Improvement In IBS Patients Through Personalized, Non-Drug Dietary Therapy

Author: Benzinga Newsdesk | June 05, 2025 07:20am

• Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.
• Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.
• Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments.
  
   

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global leader in advanced diagnostic-guided therapies, today announced that data from its pivotal clinical trial evaluating the inFoods® IBS test in treating IBS sufferers has been published in the June 2025 issue of Gastroenterology, the official journal of the American Gastroenterological Association and the highest-impact publication in the GI field.

The randomized, multicenter, double-blind, placebo-controlled trial demonstrated that patients with Irritable Bowel Syndrome (IBS) experienced statistically significant improvement in symptoms—particularly abdominal pain and bloating—when following a personalized elimination diet guided by the inFoods IBS test. The test identifies specific foods that provoke an abnormal immune response, believed to be a key trigger of IBS symptoms.

Posted In: BMRA